| Anti-angiogenic therapy in uveal melanoma. | |
| | |
MedLine Citation:
|
PMID: 22042017 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
For several decades, targeting of tumor-related vessels has been regarded as a potential anticancer therapy. Such anti-angiogenic therapy is based on the assumption that a tumor cannot grow beyond the limits of diffusion (about 1-2 mm) of oxygen and nutrients from capillaries, unless angiogenesis takes place. Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis, regulating vasopermeability as well as the proliferation and migration of endothelial cells. In several types of cancer (colon carcinoma, soft tissue sarcomas and gastric cancer), serum VEGF levels are a marker for disease stage and an indicator of metastasis. VEGF levels are significantly elevated in uveal melanoma patients with metastatic disease compared to patients without metastases. Anti-angiogenic therapy, such as bevacizumab, is currently used for the treatment of metastases of several malignancies. Anti-angiogenic therapy has not yet been tested for the treatment of primary uveal melanomaor related metastatic disease. Clinicians, however, have a broad experience with anti-angiogenic agents in patients with uveal melanoma by treating the complications of radiation therapy. We will discuss tumor angiogenic processes and related molecular pathways in uveal melanoma. The role of VEGF and the potential use of current commercially and experimentally available anti-angiogenic drugs for the treatment of primary uveal melanoma and/or metastatic disease will be explained below. |
| | |
Authors:
|
Mariam El Filali; Pieter A Van der Velden; Gregorius P M Luyten; Martine J Jager |
Related Documents
:
|
22127927 - Increased survival of glioblastoma patients who respond to antiangiogenic therapy with ... 19397647 - Immunohistochemical stains in mohs surgery: a review. 22072937 - Biomarkers in tumor angiogenesis and anti-angiogenic therapy. 1717607 - Expression of simple epithelial keratins 8 and 18 in epidermal neoplasia. 15793587 - Chfr is required for tumor suppression and aurora a regulation. 6091877 - Separation of clonogenic tumor cells from small cell lung cancer bone marrow and small ... |
Publication Detail:
|
Type: Journal Article Date: 2011-10-21 |
Journal Detail:
|
Title: Developments in ophthalmology Volume: 49 ISSN: 1662-2790 ISO Abbreviation: Dev Ophthalmol Publication Date: 2012 |
Date Detail:
|
Created Date: 2011-11-01 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8010321 Medline TA: Dev Ophthalmol Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 117-36 Citation Subset: IM |
Copyright Information:
|
Copyright © 2012 S. Karger AG, Basel. |
Affiliation:
|
Department of Ophthalmology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Analysis of intraocular biopsies.
Next Document: Immunotherapy of uveal melanoma.